Efficacy of Second-Line Advanced Therapy in Patients with Crohn’s Disease After Failure of a First Anti-TNF: A Descriptive Analysis
Journal of Clinical Medicine · 16.04.2026 · 15 (8) · 3029
DOI: 10.3390/jcm15083029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.04.2026. Verfasst von Corina Meianu und 16 weiteren Autor:innen. Beteiligte Einrichtung: UMF "Carol Davila", Gastroenterology & Hepatology Department, 020021 Bucharest, Romania. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Sequencing therapy for Crohn’s disease (CD) is currently being intensively discussed due to the development of novel drugs and lack of standardized criteria for drug positioning in first- and further-line treatment. The aim of this study was to compare the efficacy of a second-line advanced therapy in Romanian patients with CD who have failed an anti-TNF agent.
Methods
We performed a multicenter retrospective study that included adult patients with CD who had secondary loss of response after an initial response with an anti-TNF drug. The main outcome was clinical remission at 12 weeks of second-line treatment (CDAI < 150). The secondary outcomes included clinical response (decrease in CDAI ≥ 70 points), persistence of therapy at 1 year and rates of adverse events.
Results
From 2008 to 2024, 216 patients were either switched to another anti-TNF or swapped to another therapeutic class, due to the failure of a first anti-TNF drug. Secondary lines of treatment included infliximab (IFX), adalimumab (ADA), vedolizumab (VDZ), ustekinumab (UST). The highest rate of clinical remission (81%) was obtained with the sequence ADA-IFX in 26/32 (81%) patients and ADA-UST in 62/82 (76%) patients, followed by IFX-UST in 22/33 (67%) and IFX-ADA 34/51 (67%). Persistence in therapy at 1 year was better for the sequence ADA-UST (73%) and IFX-UST (67%) and ADA-IFX (63%) compared to IFX-ADA (59%) and IFX-VDZ (44%) (p < 0.001).
Conclusions
There were significant baseline differences between the treatment groups, so this study represents an unadjusted comparison between the results obtained with different biologics in second-line treatment for Crohn’s disease. In patients with CD who have failed a first anti-TNF, the highest rate of clinical remission at 12 weeks was obtained with second-line IFX and UST whilst vedolizumab showed lower efficacy. UST demonstrated the most favorable long-term treatment persistence at 1 year.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UMF "Carol Davila", Gastroenterology & Hepatology Department, 020021 Bucharest, Romania.
- Gastroenterology & Hepatology Department, Clinic Fundeni Institute, 022328 Bucharest, Romania.
- Department of Gastroenterology, Faculty of Medicine, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania.
- Institute of Gastroenterology and Hepatology, "St. Spiridon" University Hospital, 700111 Iasi, Romania.
- Cluj CF University Hospital, UMF "Iuliu Hatieganu" Cluj, 400347 Cluj, Romania.
- Gastroenterology & Hepatology Department, Elias Emergency Hospital, 011461 Bucharest, Romania.
ORCID-Profile: Anca Trifan, Alina Tantau, Ana Maria Singeap, Cristian George Tieranu, Horia Minea, Lucian Negreanu, Andreea Bota
Zitieren
APA
Meianu, C., Preda, C. M., Diculescu, M., Istratescu, D., Trifan, A., Tantau, A., Singeap, A. M., Tieranu, C. G., Minea, H., Buzuleac, A. M., Negreanu, L., Popescu, R., Bota, A., Stroie, T., Tugui, L., Cazimirovitz, A. M., & Ciora, C. A. (2026). Efficacy of Second-Line Advanced Therapy in Patients with Crohn’s Disease After Failure of a First Anti-TNF: A Descriptive Analysis. Journal of Clinical Medicine, 15(8), 3029. https://doi.org/10.3390/jcm15083029
Vancouver
Meianu C, Preda CM, Diculescu M, Istratescu D, Trifan A, Tantau A, et al. Efficacy of Second-Line Advanced Therapy in Patients with Crohn’s Disease After Failure of a First Anti-TNF: A Descriptive Analysis. Journal of Clinical Medicine. 2026;15(8):3029. doi:10.3390/jcm15083029
BibTeX
@article{Meianu2026,
author = {Meianu, Corina and Preda, Carmen Monica and Diculescu, Mircea and Istratescu, Doina and Trifan, Anca and Tantau, Alina and Singeap, Ana Maria and Tieranu, Cristian George and Minea, Horia and Buzuleac, Ana-Maria and Negreanu, Lucian and Popescu, Remus and Bota, Andreea and Stroie, Tudor and Tugui, Letitia and Cazimirovitz, Andreea-Maria and Ciora, Cosmin Alexandru},
title = {Efficacy of Second-Line Advanced Therapy in Patients with Crohn’s Disease After Failure of a First Anti-TNF: A Descriptive Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {8},
pages = {3029},
doi = {10.3390/jcm15083029}
}
EUVIMED